Applied Therapeutics, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2026-05: Study NCT07191912; Company role Lead sponsor; Phase Phase 3; Status Withdrawn.
- 2022-01-01: Study NCT05397665; Company role Lead sponsor; Phase Phase 2, Phase 3; Status Completed.
- 2021-10-01: Study NCT05418829; Company role Lead sponsor; Phase Phase 3; Status Unknown.
- 2021-03-20: Study NCT04902781; Company role Lead sponsor; Phase Phase 2, Phase 3; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2026-05 | NCT07191912 Confirmatory Study of Govorestat in CMT-SORD | Lead sponsor | Phase 3 | Withdrawn | Charcot-Marie-Tooth Disease With Sorbitol Dehydrogenase Deficiency (CMT-SORD) | 0 | 2029-01 |
| 2022-01-01 | NCT05397665 Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients With Sorbitol Dehydrogenase (SORD) Deficiency | Lead sponsor | Phase 2, Phase 3 | Completed | Hereditary Neuropathy Caused by SORD Deficiency | 56 | 2026-06-01 |
| 2021-10-01 | NCT05418829 AT-007 in Adult Subjects With Classic Galactosemia (CG) | Lead sponsor | Phase 3 | Unknown | Classic Galactosemia | 7 | 2022-12 |
| 2021-03-20 | NCT04902781 Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia | Lead sponsor | Phase 2, Phase 3 | Completed | Classic Galactosemia | 47 | 2025-05-21 |
| 2019-09-20 | NCT04083339 Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy | Lead sponsor | Phase 3 | Active not recruiting | Diabetic Cardiomyopathies | 675 | 2025-12 |
| 2019-06-21 | NCT04117711 Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia | Lead sponsor | Phase 1, Phase 2 | Completed Results posted | Classic Galactosemia | 114 | 2021-12-14 |